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A STUDY OF OBESITY IN GENERAL PRACTICE
By KENNETH BEW, M.B., B.Ch., B.A.O.
MUCH has been written on the subject of obesity, so much that it is impossible
to review the literature here. Yet, after all the investigations on the subject, the
cause of overweight still evades us, except in a few conditions (e.g., myxcedema),
where it occurs as a secondary manifestation of underlying disorder. Basically,
of course, if energy input is greater than output, there is increase in weight, but
this brings us no nearer the solution to the problem. Why can some eat to their
hearts' content and yet retain a slim silhouette, whilst others, who do equally as
much exercise, become obese on the same diet? Have the slim some inborn
metabolic defect which leads to extravagance in their use of food, or are they
incapable of laying down a store? Conversely, have the obese, by some peculiar
process of metabolism, the power to extract from their food more value than the
"normal" person?
What is the ideal weight? There are two distinct factors which decide this-
the gesthetic and the medical. The first, and probably the dominant factor, varies
from time to time and from place to place. Beauties of yesterday would not be
considered as serious contestants in a present-day contest-nor would the possessor
of that Central African hallmark of femininity, steatopygia. From the medical
standpoint, the height and weight tables have developed only over the past
century, and have been drawn up by the assurance companies, as the result of
their experience of the effect of weight on the expectation of life. These tables,
it should be realised, are based on commercial considerations, not medical ones,
but they do show that the elimination of obesity is desirable. Considered as a
disease, obesity has its complications- dyspncea, "chestiness," strain on the cardio-
vascular system (especially in the elderly), leading in extreme cases to frank
failure, mild diabetes of maturity-onset type. In the young, displaced epiphyses
are commoner in the obese. The psychological effects, too, can be severe, no less
on adults than on the young, who suffer the taunts of their school-fellows.
Therefore, it would seem to me that obesity is a problem worthy of a serious
approach by the general practitioner.
In spite of the absence of a strict definition of obesity, the overweight patient
is not difficult to detect, and the question which arises is what shall be done about
it? Put simply, the answer should be "Eat less and do more," but in my experi-
ence, so many people who carry excess weight have normal behaviour patterns
in respect of exercise that I have come to believe that the amount of exertion
undertaken by the patient is of only secondary importance, and it would be
pointless to recommend extra exercise as a method of losing weight. Indeed, it
would appear that this course would defeat its object, because appetite is likely
to increase as a physiological response to the increased demand for energy. In
any case, the grossly obese have reached the stage where the effort involved in
taking exercise is so great that they are incapable of it. The more satisfactory
method of attacking this problem is reduction of food intake. Since the quantity
43of food eaten is largely a matter of habit, and since habits are notoriously difficult
to break, the advisability of using appetite suppressant drugs immediately comes
up for consideration. Much has been written on their side effects, and especially
on the catastrophe of addiction, particularly with regard to d-amphetamine.
Indeed, doubt has been expressed as to whether they have any effect at all on
appetite.
A clinical trial was undertaken with the object of solving this problem. The
specific questions which it was designed to answer were:-
1. Are the marketed appetite suppressants really effective?
2. How long do they act?
3. Which is best?
4. What is the incidence and nature of side effects?
METHOD.
About two-thirds of the patients who were admitted to the trial were over-
weight and themselves desired to lose weight, usually on asthetic grounds or
economic grounds (e.g., their clothes no longer fitted), and about one-third were
overweight and required to reduce on medical grounds (e.g., increasing dyspncea,
hypertension). Care was taken that no person who showed any psychiatric in-
stability was admitted on the grounds that they may become habituated or
addicted to the agents used. The materials used were dexamphetamine sulphate,
a placebo, benzphetamine (Didrex) phenmetrazine (Preludin), and diethylpropion
(Tenuate). These were all supplied identical in appearance and labelled respectively
4-M, 5-M, 6-M, 7-M, and 18-K.
Each bottle contained fifty tablets, enough to last sixteen days. Since one of
the signs of habituation or addiction is increased tolerance of the particular
material, and consequent increase of dosage, any patient who returned before
the expiration of two weeks saying that his tablet supply was exhausted would
be immediately suspect. There was also a supply of the placebo tablets which
were known to me as such and which were used either on patients when they
had lost the requisite amount of weight, or to be given should any patient show
signs of habituation or addiction, to see whether this subterfuge would relieve
the situation. After an initial weighing and examination successive patients re-
ceived the tablets in a predetermined order and were instructed to take them at
a dose of 1 tablet three times daily, taken one hour before mealtime, but not later
than 4.30 p.m.
They were reweighed at two-week intervals and enquiry made as to side effects
and particularly to detect any suspicion of habituation. When the patient ceased
to lose weight or, as in many cases, gained weight, he was transferred to the
next agent in the same order as before. Initially no instruction was given as to
diet, but it very soon became apparent that this was necessary and, subsequently,
all patients were given a standard weight-restricting diet. There was a short
period towards the end of the trial when benzphetamine or known placebo was
given to all patients still taking part in the study. The measurements taken under
these circumstances were included in the results. The trial was, therefore, con-
44ducted under double-blind conditions with the exception of this short terminal
period. That is at this later stage a known active drug was issued to those patients
whose weight loss was inadequate or a placebo if the weight loss was satisfactory.
RESULTS.
Of those patients under treatment for more than six weeks, seven entered the
trial on dexamphetamine, five on phenmetrazine, six on benzphetamine, and eight
entered on diethylpropion, and eight on placebo. Thirty-four patients took these
various agents for a total of 271 weeks before they ceased to lose weight, a mean
of 7.97 weeks each. The total weight loss was 265 lb., a mean of 7.79 lb. per
patient at a mean of 0.95 lb. per week each. When these results are broken down
into two groups, the active agents on the one hand and placebo on the other,
there is a very obvious difference: the placebo effect lasts 4.13 weeks against
9.15 weeks for the active agents; the patients taking active tablets lost an overall
total of 10.19 lb. (1.11 lb. each per week), whereas among those taking placebo
tablets the weight loss was exactly countered by the weight gain. With the
numbers at my disposal one cannot compare the various agents with statistical
validity, but some idea of their effectiveness can be gained from Table 1.
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NumBER DURATION TOTAL AVERAGE MEAN RATE MEANWT.
OF OF WEIGHT DURATION OFWEIGHT LOSS PER
PATIENTS TREATMENT Loss TREATMENT LOSS PAT.
(weeks) (lbs.). (weeks) (lbs./weeks) (lbs.)
A B C B/A C/B C/A
4 M d-amphetamine:
Primary course
Subsequent course
5 M placebo:
Primary course
Subsequent course
Known placebo as:
Course
Subsequent course
Combined known and
unknown placebo:
Primary course
Subsequent course
6 M benzphetamine:
Primary course
Subsequent course
-7 ... 73
9 ... 47
- 8 ... 33
9 ... 44
-10 ... 52
- 8
- 19
- 6
- 13
... 33
... 96
... 43
... 59
... 74 ... 10.43 ... 1.01
... 11 ... 5.22 ... 0.23
... 0
... -2
(gain)
... 4.13 ... 0
... 4.89 ...-0.05
(gain)
... 3 ... ...
... 3 ... 5.20 ... 0.06
... 0
... 1
... 63
... 50
... 4.13
... 5.05
... 7.17
... 4.54
... 10.57
... 1.22
... 0
... -0.22
(gain)
... 0.30
... O ... 0
... 0.01 ... 0.05
... 1.47 ... 10.50
... 0.85 ... 3.85
Prescribed benzphetamine
as:
Course - -
Subsequent course - 10
Combined known+
unknown benzphetamine:
Primary course - 6
Subsequent course - 23
7 M phenmetrazine:
Primary course - 5
Subsequent course - 8
18 K diethylpropion:
Primary course - 8
Subsequent course - 12
Total including placebo:
Primary course - 34
Subsequent course - 71
Total excluding placebo:
Primary course - 26
Subsequent course - 52
... ... ... ... ...
... 34 ... 16 ... 3.40 ... 0.47 ... 1.60
... 43
... 93
... 53
... 48
... 69
... 39
... 63
... 66
... 60
... 48
... 7.17
... 4.04
... 10.6
... 6.00
... 68 ... 8.63
... 11 ... 3.25
... 271 ... 265 ... 7.97
... 323 ... 137 ... 4.57
... 238 ... 265 ... 9.15
... 227 ... 136 ... 4.38
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... 1.47 ... 10.50
... 0.71 ... 2.87
... 1.13 ... 12.0
... 1.00 ... 6.00
... 0.99 ... 8.50
... 0.28 ... 1.09
... 0.95 ... 7.79
... 0.42 ... 1.93
... 1.11 ... 10.19
... 0.59 ... 2.62After weight loss had ceased, the patients were transferred to the next drug (this
procedure was repeated with sonme patients several times) and the same difference
was observable between the placebo tablets and the active. It is worthy of note
that the known placebo tablets produced quantitatively similar results to the blind-
label placebo tablets and the same occurred with the benzphetamine either issued
under blind-label or precribed on E.C. 10. The graph shows the rate of weight
loss against the time from entry into the trial and demonstrates a progressive loss
of effect as time goes by. Whether this is due to a loss of true pharmacological
effectiveness or to progressive failure of determination on the part of the patient
it is not possible to state.
TABLE 2.
SIDE
EFFECT
D-AMPHET-
AMINE BENZPHET- DIETHYL- PHENMET-
SULPHATE AMINE
Depression - 1
Tension - - ... 2
Insomnia - - ... 1
Drowsiness - 1 ...
Sweating - - .
Increase of
appetite - - ... 1
TOTAL -2 ... 4
Number ofpatients
taking drug - 16 ... 29
Proportion with
side effects -1: 8.0 ... 1: 7.25
PROPION RAZINE
TOTAL TOTAL
WITHOUT WITH
PLACEBO PLACEBO PLACEBO
... 1 ... I ... - ... 3 ... 3
... ... ... 2... 2... 4
... ... ... ... 1 ... 1
1 ... 1
... 1 ... I
... ... 1
... 2 ... 3
...
. ... 1 ... 1
... ... 2 ... 2
... 1
... 3
... 2 ... 3
... 11 ... 14
... 20 ... 13 ... 27 ... 78 ... 105
... 1: 10.0 ... 1:4.33 ...1:9.00...1:7.09 ...1:7.50
Side effects were reported on fourteen occasions and are listed in Table 2.
Certainly the frequency and severity of these were the same whether patients
were currently taking the placebo or the active tablets. It is doubtful whether
the nature is very different. All were highly subjective (including two who
complained of excessive sweating) and none were serious. Whilst insomnia and
tension could be anticipated when using this type of material, drowsiness and
depression were most unexpected, particularly in the case of dexamphetamine,
a drug widely used to combat these very states. Most of the side effects occurred
at times when patients were losing weight most rapidly, and it is not improbable
that they were due to hunger, or were, indeed "withdrawal" phenomena vis-a-vis
food. There was only one patient in whom there developed signs suggesting
early habituation. He was at the time taking dexamphetamine sulphate and known
placebo tablets were substituted. The incident passed off without trouble. I feel
that this particular difficulty is well within the competence of the average general
practitioner who, knowing his patients as he does, is capable of detecting with
fair accuracy the patient who may become habituated or addicted and with-
47holding from him this class of medication. Further, he should (and can) distinguish
between those patients desiring these substances for genuine help in reducing
weight and those who want them "for kicks."
CONCLUSION.
To lose weight demands considerable effort on the part of the patient, an effort
which must be sustained. A number of patients who entered the trial were unable
to maintain this effort for more than six weeks. Certainly, patients require
assistance in achieving reduction of weight and this trial shows that there is
real benefit to be gained from the various anorectic agents and that this is greater
than can be obtained using a placebo. This effect diminishes with time and is
virtually nil after some two to three months. During this period the patient can
expect to lose 10 lb. It appears that there is little or nothing to be gained by
transfer to another agent when weight loss has ceased since only another 21 lb.
are likely to be lost over the next month, but there is great individual variation
in these figures.
Side effects occurred with a frequency which was not vastly different in the
case of active agent or placebo tablets, and they appear to be more related to
the current rate of weight loss than to the drug concerned.
SUMMARY.
A trial is described, using various anorectic agents and placebo tablets on a
double-blind basis. It was shown that the active agents were more effective in
all respects than placebo tablets. Side effects were not of moment and were not
significantly more frequent in any one group. Their possible cause is discussed.
No conclusion was possible as to the superiority of any of the active materials
used.
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